An update from Dyadic International (DYAI) is now available.
Dyadic International has inked a lucrative deal with Proliant Health and Biologicals, granting Proliant the rights to utilize Dyadic’s cutting-edge fungal production technology for creating recombinant serum albumin. This partnership will not only provide Dyadic with an immediate $500,000 upfront but also promises additional payments upon the achievement of key development milestones and a portion of the profits from product sales. This strategic move signifies a promising leap forward for both companies in the biotech industry.
See more data about DYAI stock on TipRanks’ Stock Analysis page.